Dose-matched Placebo to TS-142

DRUG2 trials

Sponsors

Taisho Pharmaceutical Co., Ltd.

Conditions

Insomnia DisorderPatients with Mild Obstructive Sleep Apnea Hypopnea

Phase 1

A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.

CompletedNCT04746105

Taisho Pharmaceutical Co., Ltd.Patients with Mild Obstructive Sleep Apnea Hypopnea

Start: 2021-02-24End: 2021-10-30Updated: 2025-02-28

Phase 2

Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder

CompletedNCT04573725

Taisho Pharmaceutical Co., Ltd.Insomnia Disorder

Start: 2017-07-07End: 2019-02-13Updated: 2025-02-28

Related Papers

Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study

Psychopharmacology2022-03-1724 citations